Work

Figure 4 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial

Year: 2026

Type: other

Abstract: Change in biomarkers from baseline to week 4 in the total cohort. IFN, interferon; TNF, tumor necrosis factor. *, P < 0.05.

DOI: 10.1158/1078-0432.33143625

Authors: Mario E. Lacouture, Alexander Pan, Tara Maier, Anna Chen, George Dranitsaris, Neil J. Shah, Chau Dang, Devika Gajria, Allison Gordon, Neil Iyengar, Pedram Razavi, Mark Robson, Ezra Rosen, Serena Wong, Ucalene Harris, Kwami Ketosugbo, Cindy Bravo, Manu Jain, Alina Markova

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7172345220

Cites:

Cited by:

Related to: